Monotherapy with tenofovir disoproxil fumarate for Adefovir (cas 106941-25-7)-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial

Add time:08/10/2019    Source:sciencedirect.com

Background & AimsTenofovir disoproxil fumarate (TDF) monotherapy has displayed non-inferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with hepatitis B virus (HBV) resistant to ETV and/or adefovir (ADV). Nonetheless, the virologic response rate was suboptimal in patients receiving up to 144 weeks of TDF monotherapy. We aimed to assess the efficacy and safety of TDF monotherapy given for up to 240 weeks.

We also recommend Trading Suppliers and Manufacturers of Adefovir (cas 106941-25-7). Pls Click Website Link as below: cas 106941-25-7 suppliers

Prev:Adefovir (cas 106941-25-7) dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction
Next:Injectable PLGA Adefovir (cas 106941-25-7) microspheres; the way for long term therapy of chronic hepatitis-B)